EyePoint to Cut 53% of Workforce After Second Phase 3 Miss for Duravyu in Wet AMD

Following a second Phase 3 miss for Duravyu in wet AMD, EyePoint will cut more than half its workforce, end the wet AMD studies early, and focus resources on its DME program.